23 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
illustrated substantial value demonstrating a commitment to execution and performance.
Coya’s core pipeline is centered around its immunomodulatory
8-K
EX-99.1
sitinap1 i6ii1j4
12 Jun 23
Regulation FD Disclosure
5:01pm
10-Q
usaa4xo5r9g bf8bojqc
10 May 23
Quarterly report
7:14am
10-K
bu1c2hs5cb53kns4ro5x
29 Mar 23
Annual report
4:08pm
10-K
EX-3.2
jhvxt5e
29 Mar 23
Annual report
4:08pm
424B4
mayd78craigk768suv
30 Dec 22
Prospectus supplement with pricing info
4:17pm
S-1/A
EX-10.1
jrau1j2wg
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
e7djl5d
5 Dec 22
IPO registration (amended)
8:16am
S-1
iiw3pmn
18 Nov 22
IPO registration
5:06pm
S-1
EX-3.1
7bilxxmc8
18 Nov 22
IPO registration
5:06pm
S-1
EX-3.4
oclju
18 Nov 22
IPO registration
5:06pm
DRS/A
EX-3
xferl
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
p7df7e yj0
28 Oct 22
Draft registration statement (amended)
12:00am